Compounded semaglutide has been available from compounding pharmacies since 2022, but the legal landscape shifted dramatically in early 2025 when the FDA declared the semaglutide shortage resolved. That declaration triggered enforcement deadlines that have already passed for some pharmacies and are expiring for others, making where and whether you can still buy compounded semaglutide a moving target. Here’s what you need to know right now.
Why the FDA Shortage Status Matters
Compounding pharmacies were legally allowed to make their own versions of semaglutide because the brand-name products, Ozempic and Wegovy, were in shortage. The FDA added Wegovy to its drug shortage list in March 2022 and Ozempic in August 2022. During a shortage, compounding pharmacies can produce copies of FDA-approved drugs that would otherwise be off-limits.
In February 2025, the FDA issued a declaratory order stating the shortage is resolved. Novo Nordisk, the manufacturer of both brand-name products, demonstrated that its supply now meets or exceeds demand and that it holds significant reserves of finished and semi-finished product. That resolution started a countdown for compounding pharmacies to stop making semaglutide copies.
Current Enforcement Deadlines
The FDA set two separate wind-down periods depending on the type of pharmacy:
- 503A pharmacies (state-licensed pharmacies compounding patient-specific prescriptions): Their enforcement grace period ended on April 22, 2025. However, the FDA also tied the deadline to an ongoing federal court case, Outsourcing Facilities Association v. FDA, stating the grace period would extend until the court’s ruling on a preliminary injunction, whichever date came later.
- 503B outsourcing facilities (large-batch compounders that supply clinics and healthcare offices): Their deadline was May 22, 2025, or the date of the same court ruling, whichever is later.
That lawsuit is still playing out in a federal court in Texas, and its outcome will determine whether compounders can continue making semaglutide beyond these dates. If you’re reading this, the legal situation may have changed again. The practical effect: some compounding pharmacies are still filling orders while the court case is active, while others have already stopped.
Two Types of Compounding Pharmacies
Not all compounding pharmacies operate the same way, and the distinction matters for what you can access.
503A pharmacies are traditional compounding pharmacies licensed by their state. They fill individual prescriptions for specific patients and dispense medications for home use. They follow state pharmacy board regulations and sterile compounding standards but are not subject to the same level of federal manufacturing oversight as larger facilities. They cannot produce large batches, which typically means higher per-unit costs.
503B outsourcing facilities operate more like small manufacturers. They can produce large batches of compounded medications, sometimes without a patient-specific prescription, and sell them to clinics and healthcare offices for in-office administration. These facilities must follow current good manufacturing practices (the same federal standards that apply to drug manufacturers), submit to FDA inspections, and test each batch for quality before releasing it. Many telehealth weight-loss platforms that offered compounded semaglutide were sourcing from 503B facilities.
You Still Need a Prescription
Compounded semaglutide is a prescription medication regardless of where you get it. You need a valid prescription from a licensed healthcare provider, whether that’s your primary care doctor, an endocrinologist, or a provider through a telehealth platform. Any source offering compounded semaglutide without requiring a prescription is operating illegally.
The most common pathways people have used to get compounded semaglutide include asking their doctor to send a prescription to a compounding pharmacy directly, or signing up with a telehealth weight-loss service that pairs a virtual consultation with a partnered compounding pharmacy. In either case, a licensed provider evaluates your health history before writing the prescription.
What’s Actually in Compounded Semaglutide
Compounded semaglutide is not identical to Ozempic or Wegovy. It uses the same active ingredient but may be formulated differently. Some compounding pharmacies add vitamin B12 (cyanocobalamin) to their semaglutide preparations. The rationale is theoretical: semaglutide slows stomach emptying and reduces stomach acid production, which could over time affect B12 absorption. But there is no clinical evidence showing that combining semaglutide with B12 improves outcomes or prevents deficiency.
The FDA has also raised concerns about the specific form of semaglutide some compounders use. The active ingredient in FDA-approved products is semaglutide base, but some compounders have used salt forms like semaglutide sodium or semaglutide acetate. These are not the same molecule, and dosing does not convert directly. The FDA recommends that healthcare providers be especially careful about dose calculations and titration schedules when prescribing compounded versions.
How to Verify a Compounding Pharmacy
If you’re filling a compounded semaglutide prescription, checking the pharmacy’s credentials is worth the effort. Start with two things: confirm the pharmacy holds a valid state license, and look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB). PCAB accreditation, administered through the Accreditation Commission for Health Care, verifies that a compounding pharmacy meets rigorous standards for sterile and non-sterile preparations. You can search for accredited pharmacies on the ACHC website.
For 503B outsourcing facilities, the FDA maintains a public registry. Any legitimate outsourcing facility will appear on that list. If a facility claims to be a 503B compounder but doesn’t show up in the FDA’s registry, that’s a significant red flag.
Red Flags to Watch For
The FDA has warned consumers about counterfeit semaglutide products circulating in the U.S. drug supply chain. When evaluating any source, watch for these warning signs:
- No prescription required: Any seller offering semaglutide without a valid prescription from a licensed provider is operating outside the law.
- Unusually low prices: Compounded semaglutide typically costs $150 to $500 per month depending on the dose and pharmacy. Prices dramatically below this range may indicate a counterfeit or diluted product.
- Packaging errors: Spelling mistakes, incorrect addresses, or missing lot numbers on labels suggest counterfeit products.
- No verifiable pharmacy license: If you can’t confirm the pharmacy’s state license or find it in any accreditation database, don’t use it.
- Direct-to-consumer sales without a pharmacist: A legitimate pharmacy will have a licensed pharmacist available to answer questions about your medication.
What Happens if Compounding Is Shut Down
If the courts side with the FDA and compounding pharmacies lose the ability to produce semaglutide, your options narrow to the brand-name products. Wegovy is FDA-approved for weight management, and Ozempic is approved for type 2 diabetes (though it is frequently prescribed off-label for weight loss). Both are manufactured by Novo Nordisk. The list price for these medications runs over $1,000 per month without insurance, though manufacturer savings programs and some insurance plans bring the cost down significantly.
If you’re currently using compounded semaglutide, it’s worth talking with your prescriber now about a transition plan. Switching from a compounded version to a brand-name product may require dose adjustments, especially if the compounded version used a salt form of semaglutide rather than the base form. Your provider can help map your current dose to the equivalent brand-name dose and set up an appropriate titration schedule.